- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Outcomes – the new targets

By Di Spencer, Pf Web Editor

In the introduction to the DH consultation paper Transparency in Outcomes, Andrew Lansley asserts that nationally determined process targets have distorted clinical priorities, “disempowered healthcare professionals and stifled innovation”.

The new paper should, therefore, be good news for pharma – innovation is what the industry is about after all, and empowering pharma’s direct customers, HCPs, to make decisions locally can only be a positive step.

The current Government’s dislike of such targets has been controversial, as many did actually bring about improvements in the areas on which they focused, such as waiting times. On the flip-side, the tendency was for the target to become the priority rather than patient’s care.

The hope is that the emphasis on ‘outcomes’ will take the focus away from the process – the flaw in targets. The paper proposes that the newly-established NHS Commissioning Board will be held accountable for national outcomes, while the GP commissioning consortia will be responsible to the Board for improvements in these areas.

In her recent Pf feature, Thoreya Swage points out that the proposed changes could represent a golden opportunity for the industry, which is ideally placed to support GP consortia in setting specific indicators and advising on how various conditions can be managed better. Read more

The consultation closed on 11th October so if, like me, you were late in submitting your response, we can only wait for the fate of NHS outcomes to be decided in the final document in December.



Contact the author: diana.spencer@healthpublishing.co.uk

- Advertisement -


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription